FDA Approves Expanded Indications for CF Drugs Alyftrek, Trikafta
New label extensions for Alyftrek and Trikafta make approximately 95% of the cystic fibrosis population in the United States eligible for treatment.
New label extensions for Alyftrek and Trikafta make approximately 95% of the cystic fibrosis population in the United States eligible for treatment.
New label extensions for Alyftrek and Trikafta make approximately 95% of the cystic fibrosis population in the United States eligible for treatment.
Read MoreEngland’s National Institute for Health and Care Excellence issued a positive final draft recommendation for Vertex Pharma’s Alyftrek CFTR modulator, which will now be available via the National Health Service (NHS).
Read MoreAlyftrek is a triple combination CFTR modulator comprised of deutivacaftor, tezacaftor and vanzacaftor.
Read MoreThe FDA approved Alyftrek, a once-daily triple combo CFTR modulator, for certain cystic fibrosis patients aged 6 and older.
Read More